Podcasts about jacc

  For over 20 years, the Jacklin Arts & Cultural Center, also known as The JACC, has brought the Post Falls community together through the transformative power of the arts. What began as a mission to save a historic building has blossomed into a thriving hub where creativity, connection, and culture flourish in the heart of Post Falls. Darla Dreyer has been the Executive Director for the last eight of those years, and she talks to us about the upcoming events, exhibits and classes happening there this fall and winter. To find out more visit thejacklincenter.org or on Facebook @JacklinArts.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Outcomes of Telemedicine TAVR Preoperative Evaluations.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Total Atrial Conduction Time as a Predictor of Left Atrial Functional Recovery in Atrial Fibrillation.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Early Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Sex Differences in Cardiovascular Health Status and Long-Term Outcomes in a Primary Prevention Cohort.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Role of Artificial Intelligence in Reducing Data Deluge From Cardiac Implantable Electronic Devices.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Impact of Food Desert Residence on Ischemic Stroke and Hospitalization Risk in Atrial Fibrillation Patients.

The FiltrateJoel Topf @kidneyboy.bsky.social‬Swapnil Hiremath @hswapnil.medsky.socialNayan Arora captainchloride.bsky.socialSopia Ambruso @sophia-kidney.bsky.socialSpecial Guests Brendon Neuen @brendonneuen.bsky.social Associate Professor and Program Lead, Renal and Metabolic at The George Institute for Global Health. Nephrologist and Director of Kidney Trials at Royal North Shore Hospital.Neuen has had three prior appearances on Freely Filtered: EMPA Kidney, DUPLEX and Sparsentan in FSGS, FLOW and SemaglutideMuthiah Vaduganathan @mvaduganathan on X. Cardiologist at Brigham and Women's Hospital and Harvard Medical School. Assistant Professor of Medicine.Editing byJoel TopfThe Kidney Connection written and performed by Tim YauShow NotesDONATE to NephJC! Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes NEJM | NephJC SummaryFIDELIO Bakris et al, NEJM 2020 | NephJC Summary; subgroup throws doubt on efficacy of finerenone in patients on flozinsFIGARO Pitt et al, NEJM 2021; subgroups clearly shows finerenone works, flozins or notNEJM editorial (wrongly) saying do not use Flozins unless on RASi Don't use dual RAS blockade ONTARGET Yusuf et al, NEJM 2008; VA NEPHRON-D Fried et al NEJM 2013Why we cannot study finerenone in HFrEF (RALES Pitt et al NEJM 1999) Muthu is jealous of GFR slope and albuminuria surrogate endpoints and wants to borrow them for HFpEF (Inker et al EHJ 2025)Combination therapy and CV outcomes in hypertension (Wang et al JAMA Card 2024 on low dose combinations and BP; Egan et al Blood Pressure 2022 review of topic) CONFIRMATION HF trial registry entry (Finerenone and Empagliflozin in hospitalized patients with HF)23:20: Nayan and Swap miss a chance to say ‘de-flozination' to discuss stopping a flozin which would allow a patient to be included in the trial Finerenone is a CYP3A4 substrate (Heinig et al Clin Pharmacokinetics 2023); Useful list of CYP3A4 inducers and inhibitors Everyone should get an ABPM (Bugeja et al CMAJ 2022)EASiKIDNEY study design Albuminuria mediates CKD benefits with Finerenone (Agarwal et al Ann Intern Med 2023)GFR slope and Albuminuria and the FDA (Taylor et al eClin Med 2025) Dapagliflozin and Eplerenone combination crossover trial (Provenzano et al JASN 2022)Joel gets promoted! (PBFluids reflection) Bluesky NephJC Chat discussion on ‘renal remission' Withdrawal of Finerenone and worse outcomes from FINEARTS (Vaduganathan et al JACC 2025)Combination therapies Analysis from Brendan and Muthu (Neuen et al Circulation 2024)Do not use KFRE when GFR > 60 (KDIGO Practice Point 2.2.4: Note that risk prediction equations developed for use in people with CKD G3–G5, may not be valid for use in those with CKD G1–G2) Finerenone vs Spironolactone trial in Primary Aldosteronism (Hu et al Circulation 2025)FIND CKD trial design (Heerspink et al NDT 2025) FINE-ONE trial design (Heerspink et al Diab Res Practice 2023) Tubular SecretionsNayan keeping his chin up as Yankees lose and Mariners follow (MLB Playoffs)Sophia's adventures with Beekeeping (Royal Jelly?) Brendon loves listening to ‘Susan' by Raye Muthu is back into Taekwondo Swap is still reading Martha Wells (Witch King on GoodReads)Joel will be hiking the Laugavegur trail in Iceland

Commentary by Dr. Bonnie Ky.

Commentary by Dr. Eli Muchtar.

Commentary by Dr. Vivek Narayan.

Commentary by Dr. Nicolas Palaskas & Dr. Keila Ostos-Mendoza.

Commentary by Dr. Pavel Martinez-Dominguez.

Audio Summary of the October 2025 Issue by Dr. Jian'an Wang.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Development of an Electronic Medical Record–Based Score for Heart Failure Prediction in Cancer Survivors.

Commentary by Yi Li, MA.

Dr. Harlan Krumholz introduces a JACC issue unified around the question of how low to target blood pressure, highlighting growing evidence that aiming near 120 mm Hg improves cardiovascular outcomes without harming quality of life. Several studies from the STEP and ESPRIT trials show that intensive blood pressure control widens retinal arterioles, lowers stroke risk, enhances well-being, and remains safe even in older adults. Long-term follow-up data demonstrate that early initiation of intensive therapy provides lasting cardiovascular protection, while new analyses using the PREVENT equations confirm that higher-risk patients gain the most absolute benefit. The issue underscores that intensive control is both safe and effective, and that the next challenge is implementing these proven strategies consistently in clinical practice.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

JACC Editor-in-Chief Harlan M. Krumholz, MD, SM, introduces the October 21, 2025 issue of JACC, which is devoted entirely to Dr. Milton Packer's adipokine hypothesis.  Dr. Krumholz explains the rationale behind dedicating the issue to this bold conceptual framework, which proposes that dysfunctional visceral fat and its secreted adipokines drive HFpEF. We're also thrilled to present readers with 10 accompanying expert commentaries that explore, challenge, and contextualize the hypothesis.

Commentary by Dr.  Kohei Ishibashi.

Commentary by Dr. Sheryl Chow.

Commentary by Dr. Taku Kato.

Commentary by Dr. Yoshihiro Miyamoto.

Commentary by Dr.  Alston Chiu.

This episode of JACC This Week, hosted by Harlan M. Krumholz, MD, SM, highlights key research and perspectives from the October 14, 2025 issue of JACC. It opens with a call to modernize physician certification by distinguishing core knowledge from clinical reasoning, emphasizing continuous, engaging learning over rote memorization. Featured studies in this week's issue include the cardiovascular risks linked to clonal hematopoiesis in older women, improved clotting outcomes with third-generation LVADs despite ongoing bleeding risks, and how dapagliflozin reduces heart failure events post-TAVI without improving perceived quality of life. The episode also explores inflammation as a target after myocardial infarction, the evolving role of drug-coated balloons in PCI, and cardiac CT's expanding use in prosthetic valve assessment—signaling a shift toward more precise, less invasive cardiovascular care. We also feature an article from JACC: Asia this week on cardiovascular Implications of lipoprotein(a) and its genetic variants in patients from the Middle East.

Abdullah Al-Abcha, MD, social media editor of JACC: Cardiovascular Interventions, and Joo Lee, MD discuss the outcomes of intravascular imaging-guided PCI versus coronary artery bypass grafting for left main or three-vessel disease.

Abdullah Al-Abcha, MD, social media editor of JACC: Cardiovascular Interventions, and Aloke Finn, MD discuss the comparison of vascular injury from intravascular lithotripsy, cutting, or ultra-high-pressure balloons during coronary calcium modification.

Mirza Umair Khalid, MD, social media editor of JACC: Cardiovascular Interventions, and Niccolò Ciardetti, MD discuss a recently published study examining use of Drug Coated Balloons for CTO PCI in the large ERCTO registry.

In the September 22 episode of JACC This Week, Editor-in-Chief Dr. Harlan Krumholz explores the concept of "computable quality" in healthcare, advocating for real-time, data-driven improvement in clinical care. He reviews original research on pop-up cardiovascular screenings in pharmacies and sporting events, AI-driven echocardiographic automation, and anticoagulation in pulmonary arterial hypertension. The episode also features a three-part debate on transcatheter aortic valve replacement (TAVR) in low-risk patients, highlighting evolving evidence, clinical implications, and calls for guideline reassessment. Tune in for insights on innovation, equity, and the future of cardiovascular care.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on IL-1 Pathway Inhibition in Recurrent Pericarditis Management: Real-World Adoption of Corticosteroid Sparing in RESONANCE.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Greenspace and Survival Among Older Women With Breast Cancer: Regional Variations Within the U.S. SEER-Medicare-Linked Database.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Ideal Navitor Implant Depth for Redo-TAVR Feasibility and Coronary Access: A CT Simulation Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Trends in Risk Factor Prevalence and Incidence of Acute Myocardial Infarction in Young Adults.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Clinical Outcomes of Ezetimibe Plus Statins in Patients With Lower Extremity Artery Disease.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Electrocardiogram-Based Artificial Intelligence to Identify Coronary Artery Disease.

In this episode, Editor-in-Chief Harlan Krumholz explores the evolving landscape of cardiovascular medicine, beginning with a call for responsible stewardship of artificial intelligence. Highlights include a major registry study on percutaneous aspiration for right-sided endocarditis, the predictive power of polygenic risk scores in heart failure, and the diverse causes of myocardial infarction in younger adults—especially women. The episode also covers a randomized trial on Intensive versus conventional intraoperative blood pressure management on cardiovascular events after major abdominal surgery, a state-of-the-art review on stressor-associated atrial fibrillation, and insights into long-term antithrombotic therapy after PCI. Each segment underscores the need for precision, equity, and innovation in clinical practice.